GSK Decreases Reliance On Late-Stage Licenses, Citing Strength In R&D
Executive Summary
GlaxoSmithKline is reducing its reliance on late-stage in-licensing deals following an R&D restructuring program that has yielded a burgeoning pipeline, CEO J.P. Garnier told analysts
You may also be interested in...
GSK Takes “Blank Check” Approach To Pursuit Of Biotech Agreements
GlaxoSmithKline will continue to actively build its biotech business with further product in-licensing and acquisitions, CEO J.P. Garnier indicated
GSK Takes “Blank Check” Approach To Pursuit Of Biotech Agreements
GlaxoSmithKline will continue to actively build its biotech business with further product in-licensing and acquisitions, CEO J.P. Garnier indicated
GSK Is Not Aventis’ “White Knight”; 2004 Will Be A Transition Year
GlaxoSmithKline will not make a "white knight" bid for Aventis, GSK said during its Feb. 12 year-end earnings presentation